The use of maintenance showed a trend of better PFS of about 6 months but it was not statistically significant, mostly due to heterogeneous medications.
← all excerpts
Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.
1
—
—